Andrew Combs
Corporate Officer/Principal chez PRELUDE THERAPEUTICS INCORPORATED
Fortune : - $ au 31/03/2024
Profil
Andrew P.
Combs is currently the Executive Vice President & Head-Chemistry at Prelude Therapeutics, Inc. He was previously the Vice President at Incyte Corp.
Prior to that, he held Director-Medicinal Chemistry positions at DuPont Pharmaceuticals Co. and DuPont Merck Pharmaceutical Co. and was also the Director-Medicinal Pharmaceuticals at Bristol Myers Squibb Co. Combs holds a doctorate from the University of California, Los Angeles and an undergraduate degree from the University of Wisconsin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Andrew Combs
| Sociétés | Poste | Début |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Corporate Officer/Principal | 01/04/2019 |
Anciens postes connus de Andrew Combs
| Sociétés | Poste | Fin |
|---|---|---|
| INCYTE CORPORATION | Director of Finance/CFO | 01/01/2015 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2003 |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | 01/08/2002 |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Corporate Officer/Principal | 01/08/2002 |
Formation de Andrew Combs
| University of California, Los Angeles | Doctorate Degree |
| University of Wisconsin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| INCYTE CORPORATION | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| Entreprise privées | 2 |
|---|---|
DuPont Pharmaceuticals Co.
DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
